Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-05-09 06:45:00
VB10.16 in combination with atezolizumab demonstrated an ORR of 21%, including 2
CRs and 6 PRs, in a heavily pre-treated population of patients with
HPV16-positive advanced cervical cancer
VB10.16 in combination with atezolizumab demonstrated a very high DCR of 64%
Anti-tumor activity of VB10.16 in combination with atezolizumab was observed
both in PD-L1 positive patients (ORR of 27%